MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

NextEdge Admin

13 Nov 2024

2 min 26 sec

precision medicine,next-generation sequencing,NSCLC,JAMA Network Open

Tempus AI, a leader in AI-driven precision medicine, announced the publication of a study in *JAMA Network Open* demonstrating the benefits of concurrent RNA and DNA next-generation sequencing (NGS) for patients with advanced non-small cell lung cancer (NSCLC). The study, which analyzed data from over 5,500 patients, found that using both RNA- and DNA-based NGS significantly increased the detection of actionable structural variants, which are genetic alterations with potential therapeutic implications.

In this study, Tempus reported that 8.8% of patients had at least one actionable variant, including ALK, RET, ROS1, or NTRK1/2/3 fusions, or MET exon 14 skipping alterations, identified by one or both assays. Importantly, the combined approach of RNA and DNA sequencing increased the identification of patients with actionable variants by 15.3% and more than doubled the detection of rare structural variants compared to DNA sequencing alone.

These findings support a broader adoption of combined RNA and DNA sequencing in clinical settings for more comprehensive genomic profiling in advanced NSCLC. “This study highlights the critical role of dual RNA- and DNA-based testing in identifying a wider range of actionable alterations, many of which might be missed with DNA testing alone," stated Halla Nimeiri, MD, Chief Development Officer at Tempus. "The integration of RNA and DNA sequencing offers clinicians better tools to personalize treatment plans and improve patient outcomes."

The study suggests that this dual-sequencing approach could enhance precision treatment in NSCLC and other solid tumors by identifying more diverse actionable genetic alterations.